Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fátima Cardoso, S. Kyriakides, Shinji Ohno, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1194-1220
Open Access | Times Cited: 1719

Showing 1-25 of 1719 citing articles:

Breast cancer
Nadia Harbeck, Frédérique Penault‐Llorca, Javier Cortés, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 2258
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 9, pp. 810-821
Open Access | Times Cited: 2212
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4287-4287
Open Access | Times Cited: 1137
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino, Erika Hamilton, Sara M. Tolaney, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 17, pp. 1951-1962
Closed Access | Times Cited: 566
Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018
Parisa Mokhtari-Hessari, Ali Montazeri
Health and Quality of Life Outcomes (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 351
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
Matteo Lambertini, Fedro A. Peccatori, Isabelle Demeestere, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1664-1678
Open Access | Times Cited: 348
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Irina Larionova, Gulnara Tuguzbaeva, Anastasia A. Ponomaryova, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 313
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 4, pp. 233-250
Open Access | Times Cited: 245
Breast cancer: presentation, investigation and management
Chie Katsura, Innocent Ogunmwonyi, Hadyn Kankam, et al.
British Journal of Hospital Medicine (2022) Vol. 83, Iss. 2, pp. 1-7
Closed Access | Times Cited: 242
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Ann Byrne, Peter Savas, Sneha Sant, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 6, pp. 341-348
Closed Access | Times Cited: 236
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Amanda Kerr, David Dodwell, Paul McGale, et al.
Cancer Treatment Reviews (2022) Vol. 105, pp. 102375-102375
Open Access | Times Cited: 201
Breast cancer: an up‐to‐date review and future perspectives
Ruoxi Hong, Binghe Xu
Cancer Communications (2022) Vol. 42, Iss. 10, pp. 913-936
Open Access | Times Cited: 196
Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries
Urania Dafni, Zoi Tsourti, Ioannis Alatsathianos
Breast Care (2019) Vol. 14, Iss. 6, pp. 344-353
Open Access | Times Cited: 178
Global guidelines for breast cancer screening: A systematic review
Wenhui Ren, Ming-Yang Chen, You‐Lin Qiao, et al.
The Breast (2022) Vol. 64, pp. 85-99
Open Access | Times Cited: 177
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
Sherene Loi, Stefan Michiels, Sylvia Adams, et al.
Annals of Oncology (2021) Vol. 32, Iss. 10, pp. 1236-1244
Open Access | Times Cited: 172
Management of common clinical problems experienced by survivors of cancer
Jon Emery, Phyllis Butow, Julia Lai‐Kwon, et al.
The Lancet (2022) Vol. 399, Iss. 10334, pp. 1537-1550
Closed Access | Times Cited: 158
Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer
Eleonora Timperi, Paul Gueguen, Martina Molgora, et al.
Cancer Research (2022) Vol. 82, Iss. 18, pp. 3291-3306
Open Access | Times Cited: 155
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Charles E. Geyer, William M. Sikov, Jens Huober, et al.
Annals of Oncology (2022) Vol. 33, Iss. 4, pp. 384-394
Open Access | Times Cited: 153
The requirements of a specialist breast centre
Laura Biganzoli, Fátima Cardoso, Marc Beishon, et al.
The Breast (2020) Vol. 51, pp. 65-84
Open Access | Times Cited: 151
The Exciting New Field of HER2-Low Breast Cancer Treatment
Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1015-1015
Open Access | Times Cited: 127
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
Raz Mutai, Tamar Barkan, Assaf Moore, et al.
The Breast (2021) Vol. 60, pp. 62-69
Open Access | Times Cited: 115
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
Shani Paluch‐Shimon, Fátima Cardoso, Ann H. Partridge, et al.
Annals of Oncology (2022) Vol. 33, Iss. 11, pp. 1097-1118
Open Access | Times Cited: 111
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M. Tolaney, Paolo Tarantino, Noah Graham, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 3, pp. 273-285
Closed Access | Times Cited: 104
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Jeremy Braybrooke, Rosie Bradley, Richard Gray, et al.
The Lancet (2023) Vol. 401, Iss. 10384, pp. 1277-1292
Open Access | Times Cited: 99
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
Karama Asleh, Nazia Riaz, Torsten O. Nielsen
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 93
Page 1 - Next Page

Scroll to top